18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nantes University Hospital
Before surgery is undertaken, a 18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography (18-FDG TEP-CT ) will be performed. The primary outcome of this study is to compare results of the TEP-CT with those obtained by the pathological analysis of the removed piece of pancreas.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults with age equal or above 18
Patients diagnosed with intraductal papillary mucinous tumor with surgical indication and for whom it will be possible to have the pathological analysis of the removed piece of pancreas.
if woman being of childbearing potential, woman taking contraceptive measures
Patient able to understand benefits and risks of protocol
Subject affiliated to French health insurance (Social Security)
Informed consent form signed
Pancreatic surgery or radiotherapy in the pancreatic zone within 4 the months preceding the TEP-CT
Chemotherapy within 2 the months preceding the TEP-CT
Acute pancreatitis within 2 the months preceding the TEP-CT
Pregnant women or breast-feeding women refusing to temporary stop it
Diabetes not equilibrated (checked by glycemia and glycosylated hemoglobin (HbA1c) at inclusion) or Fasting blood glucose below 7mmol/L (126 g/L before the TEP)
Patients with claustrophobia
Patients not accepted under the anesthesia point of view
Clareo Health | 18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas
